Peptide Therapy for Lyme Disease: What People Are Actually Using

Chronic Lyme disease is one of the most contested areas in medicine. Standard treatment is a course of antibiotics, which works for most people when caught early. But a significant number of patients continue to have symptoms after treatment: fatigue, joint pain, brain fog, muscle aches, and immune dysfunction. The medical establishment is divided on whether “chronic Lyme“ represents ongoing infection, post-infectious immune dysfunction, or something else entirely. Patients who don't improve with antibiotics often end up in functional or integrative medicine clinics, where peptide therapy has become one of several tools used to address the underlying dysfunction. The recent FDA reclassification of peptides (April 2026) has made this conversation more relevant. Peptides like BPC-157, TB-500, LL-37, and MOTs-C are now accessible through compounding pharmacies again, after being restricted since late 2023.

Lyme disease affects multiple body systems. Peptide therapy for Lyme is not about a single peptide targeting a single problem. It's about using different peptides to address different layers of the disease: Layer 1: Immune modulation. Lyme disease disrupts immune function. The bacteria can suppress certain immune responses while triggering chronic inflammation in others. Layer 2: Inflammation and tissue damage. Chronic inflammation from Lyme damages joints, nerves, and connective tissue. Layer 3: Gut disruption. Antibiotics and the disease itself can damage gut lining integrity, leading to leaky gut and further immune dysfunction. Layer 4: Cellular energy. Lyme bacteria can disrupt mitochondrial function, leading to the crushing fatigue that defines the disease. Layer 5: Neurological effects. Brain fog, cognitive dysfunction, and neuropathy are common and often the most debilitating symptoms.

BPC-157. The most commonly used peptide for Lyme. It addresses gut repair (many Lyme patients have significant GI issues), reduces systemic inflammation, and has neuroprotective properties. Oral and injectable forms are both used. Thymosin alpha-1 (TA1). An immune-modulating peptide produced by the thymus gland. It boosts T-cell function and helps rebalance immune responses. This is relevant because Lyme bacteria actively suppress certain immune pathways. TB-500 (thymosin beta-4). Used for tissue repair and inflammation reduction. Lyme patients with joint pain, tendon issues, and muscle damage often benefit. LL-37. A human antimicrobial peptide that has direct activity against bacteria, including some evidence of activity against Borrelia (the Lyme bacteria). Recently removed from FDA Category 2. MOTs-C. A mitochondrial peptide that may help with the energy production problems that cause Lyme fatigue. It supports cellular metabolism and insulin sensitivity. KPV. A peptide fragment of alpha-MSH that reduces gut inflammation. Useful for Lyme patients with significant GI symptoms.

The Lyme community's experience with peptides is mixed but cautiously positive. One user on r/LymeDisease described their protocol: “BPC-157 for gut healing, TA1 for immune support, and MOTs-C for energy. After three months, my gut issues improved about 60%. Energy is maybe 30% better. Brain fog hasn't changed much.“ A poster on r/Peptides with Lyme noted: “Peptides aren't a cure. Nothing is. But BPC-157 did more for my gut in two months than two years of probiotics and dietary changes. TA1 seemed to help my immune system stop overreacting to everything.“ Dr. Bill Rawls, who has written extensively about peptide therapy for tick-borne diseases, emphasizes that there is no one-size-fits-all approach. The peptide combination depends on which symptoms are dominant and how the individual responds.

Depending on which peptides are used and which symptoms are dominant:

• Reduced joint pain and inflammation
• Improved gut function and reduced GI symptoms
• Better energy levels (particularly with MOTs-C)
• Improved immune regulation (fewer overreactions, better pathogen clearance)
• Reduced brain fog (results vary, some people see improvement, others don't)
• Better sleep quality
• Faster recovery from herxheimer reactions (when they occur during treatment)

There are no randomized controlled trials of peptide therapy specifically for Lyme disease. The evidence base consists of:

• Mechanistic studies showing how each peptide works in relevant pathways
• Small studies and case reports from practitioners treating Lyme patients
• Patient-reported outcomes in online communities
• Extrapolation from studies in other conditions with overlapping pathology (autoimmune disease, chronic inflammation, gut dysfunction)

This is important context. Peptide therapy for Lyme is an emerging approach based on sound reasoning, not established evidence. It should be pursued with a knowledgeable practitioner, not as self-treatment.

The specific combination depends on your symptoms, but common pairings include:

• BPC-157 + KPV for gut-dominant symptoms
• TA1 + LL-37 for immune-dominant symptoms
• MOTs-C + TB-500 for fatigue and recovery-dominant symptoms
• BPC-157 + TB-500 for joint and connective tissue pain

Many Lyme practitioners also incorporate non-peptide supports: low-dose naltrexone, mitochondrial supplements (CoQ10, PQQ, NAD+), and antimicrobial herbs alongside peptide protocols.